RxDoctor Payments Data

James Adair, DO

Internal Medicine · Albuquerque, NMNPI 1578524906

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $90,950 of the $107,548 with a category attached, or 84.6%. Johnson & Johnson accounts for 98.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $44,738 and has fallen 99.7% since, to $124 in 2025. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$107,548in general payments, 2019–2025

Across 189 payments — averaging $569.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$106K
  • E.r. Squibb & Sons, L.L.C.$441
  • Janssen Scientific Affairs, LLC$228
  • AstraZeneca$150
  • AbbVie$124
  • Portola Pharmaceuticals, LLC$124
  • plus $713 from 10 others

What the payments were for

  • Consulting fees$1,4251%
  • Speaking & faculty fees$90,95085%
  • Travel & lodging$10,1739%
  • Food & beverage$4,8625%
  • Education$1370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,548 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$17,524
Medicare patients
82
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban314$327,937
EliquisApixaban116$110,220
Enoxaparin Sodium16$2,719
Warfarin Sodium109$1,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$105,768$327,937314 claims
PfizerEliquis$110$110,220116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →